Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Evaluation of tumor size response metrics to predict survival in oncology clinical trials.

Bruno R, Mercier F, Claret L.

Clin Pharmacol Ther. 2014 Apr;95(4):386-93. doi: 10.1038/clpt.2014.4. Epub 2014 Jan 13. Review.

PMID:
24419563
2.

A modeling and simulation framework to support early clinical drug development decisions in oncology.

Bruno R, Lu JF, Sun YN, Claret L.

J Clin Pharmacol. 2011 Jan;51(1):6-8. doi: 10.1177/0091270010376970. Epub 2010 Jul 13. No abstract available.

PMID:
20628172
3.

Pharmacodynamic biomarkers in model-based drug development in oncology.

Keizer RJ, Schellens JH, Beijnen JH, Huitema AD.

Curr Clin Pharmacol. 2011 Feb;6(1):30-40. Review.

PMID:
21235464
4.

Clinical pharmacogenomics and transcriptional profiling in early phase oncology clinical trials.

Burczynski ME, Oestreicher JL, Cahilly MJ, Mounts DP, Whitley MZ, Speicher LA, Trepicchio WL.

Curr Mol Med. 2005 Feb;5(1):83-102. Review.

PMID:
15720272
5.

Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development.

Bernard A, Kimko H, Mital D, Poggesi I.

Expert Opin Drug Metab Toxicol. 2012 Sep;8(9):1057-69. doi: 10.1517/17425255.2012.693480. Epub 2012 May 26. Review.

PMID:
22632710
6.

Pharmacokinetic-pharmacodynamic guided trial design in oncology.

van Kesteren Ch, Mathôt RA, Beijnen JH, Schellens JH.

Invest New Drugs. 2003 May;21(2):225-41. Review.

PMID:
12889741
7.

Clinical trials in drug development: a minimalistic approach.

Verweij J.

Curr Opin Oncol. 2012 May;24(3):332-7. doi: 10.1097/CCO.0b013e328351fb43. Review.

PMID:
22343389
8.

Towards integrative systems pharmacology models in oncology drug development.

van Hasselt JG, van der Graaf PH.

Drug Discov Today Technol. 2015 Aug;15:1-8. doi: 10.1016/j.ddtec.2015.06.004. Epub 2015 Jul 16. Review.

PMID:
26464083
9.

Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.

Kinders R, Parchment RE, Ji J, Kummar S, Murgo AJ, Gutierrez M, Collins J, Rubinstein L, Pickeral O, Steinberg SM, Yang S, Hollingshead M, Chen A, Helman L, Wiltrout R, Simpson M, Tomaszewski JE, Doroshow JH.

Mol Interv. 2007 Dec;7(6):325-34. doi: 10.1124/mi.7.6.9. Review.

PMID:
18199854
10.
11.

Oncology trials gear up for high-throughput sequencing.

Mullard A.

Nat Rev Drug Discov. 2012 Apr 30;11(5):339-40. doi: 10.1038/nrd3733. No abstract available.

PMID:
22543457
12.

A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology.

Park K.

Yonsei Med J. 2017 Jan;58(1):1-8. doi: 10.3349/ymj.2017.58.1.1. Review.

13.

Targeted agents: how to select the winners in preclinical and early clinical studies?

Goodwin R, Giaccone G, Calvert H, Lobbezoo M, Eisenhauer EA.

Eur J Cancer. 2012 Jan;48(2):170-8. doi: 10.1016/j.ejca.2011.09.024. Epub 2011 Nov 15. Review.

PMID:
22093946
14.

Use of healthy volunteers drives clinical oncology drug development decision making.

Iwamoto M, Iannone R, Wagner JA.

Clin Pharmacol Ther. 2012 Nov;92(5):571-4. doi: 10.1038/clpt.2012.157. Epub 2012 Sep 26. No abstract available.

PMID:
23010649
15.

Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.

Venkatakrishnan K, Friberg LE, Ouellet D, Mettetal JT, Stein A, Trocóniz IF, Bruno R, Mehrotra N, Gobburu J, Mould DR.

Clin Pharmacol Ther. 2015 Jan;97(1):37-54. doi: 10.1002/cpt.7. Epub 2014 Dec 9. Review.

PMID:
25670382
16.

Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development.

Wang Y, Sung C, Dartois C, Ramchandani R, Booth BP, Rock E, Gobburu J.

Clin Pharmacol Ther. 2009 Aug;86(2):167-74. doi: 10.1038/clpt.2009.64. Epub 2009 May 13.

PMID:
19440187
17.

Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.

Zandvliet AS, Schellens JH, Beijnen JH, Huitema AD.

Clin Pharmacokinet. 2008;47(8):487-513. Review.

PMID:
18611060
18.

New insights into drug development for pediatric solid tumors: what preclinical data justify clinical trials in pediatric cancer?

Houghton PJ.

Expert Rev Anticancer Ther. 2013 Oct;13(10):1135-8. doi: 10.1586/14737140.2013.845094. Epub 2013 Oct 4. No abstract available.

PMID:
24093514
19.

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

Park JW, Kerbel RS, Kelloff GJ, Barrett JC, Chabner BA, Parkinson DR, Peck J, Ruddon RW, Sigman CC, Slamon DJ.

Clin Cancer Res. 2004 Jun 1;10(11):3885-96. Review. No abstract available.

20.

Development of target-based antineoplastic agents.

Stadler WM, Ratain MJ.

Invest New Drugs. 2000 Feb;18(1):7-16. Review.

PMID:
10830137

Supplemental Content

Support Center